Ainos, Inc. Files 10-Q/A Amendment for Period Ending September 30, 2023

TL;DR

<b>Ainos, Inc. filed an amended 10-Q report for Q3 2023, detailing sales and agreements.</b>

AI Summary

Ainos, Inc. (AIMDW) filed a Amended Quarterly Report (10-Q/A) with the SEC on February 15, 2024. Ainos, Inc. filed a 10-Q/A amendment on February 15, 2024, for the period ending September 30, 2023. The company's fiscal year ends on December 31. The filing includes data related to COVID-19 Antigen Rapid Test Kits Sales. It also references sales and marketing agreements with Ainos KY. Key dates include a subsequent event on October 11, 2023, and stock incentive plan adoption on June 14, 2023.

Why It Matters

For investors and stakeholders tracking Ainos, Inc., this filing contains several important signals. This amendment provides updated financial and operational information for Ainos, Inc. for the third quarter of 2023, crucial for investors to assess the company's performance and outlook. The inclusion of specific sales data for COVID-19 Antigen Rapid Test Kits and related agreements highlights key revenue drivers and strategic partnerships for the company.

Risk Assessment

Risk Level: medium — Ainos, Inc. shows moderate risk based on this filing. The filing is an amendment to a 10-Q, suggesting potential corrections or additions to previously reported information, which warrants a medium risk assessment.

Analyst Insight

Review the specific changes and additions in this 10-Q/A filing to understand any material updates to Ainos, Inc.'s financial position or business operations.

Revenue Breakdown

Key Numbers

• 2023-09-30 — Reporting Period End Date (Conformed period of report)
• 2024-02-15 — Filing Date (Filed as of date)
• 0.01 — EPS (Implied) (Value associated with EPS)
• 10000000 — Value 1 (Associated with a financial metric)
• 300000000 — Value 2 (Associated with a financial metric)
• 20292624 — Value 3 (Associated with a financial metric)
• 20011602 — Value 4 (Associated with a financial metric)
• 4351000 — Value 5 (Associated with a financial metric)

Key Players & Entities

• Ainos, Inc. (company) — Filer name and business address
• 2023-09-30 (date) — Conformed period of report
• 2024-02-15 (date) — Filed as of date
• 0001014763 (company) — Central Index Key
• 2834 (industry) — Standard Industrial Classification (Pharmaceutical Preparations)
• TX (location) — State of incorporation
• San Diego, CA (location) — Business address city and state
• AIMDW (ticker) — Ticker symbol

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share AIMD The Nasdaq Stock Mar
• $21,224 — (including amounts of related party of $21,224 and $1,506,225 for the three months end
• $1,506,225 — amounts of related party of $21,224 and $1,506,225 for the three months ended September 30
• $33,765 — ended September 30, 2023 and 2022, and $33,765 and $1,988,150 for the nine months ende
• $1,988,150 — mber 30, 2023 and 2022, and $33,765 and $1,988,150 for the nine months ended September 30,
• $39,523 — (including amounts of related party of $39,523 and $732,765 for the three months ended
• $732,765 — amounts of related party of $39,523 and $732,765 for the three months ended September 30
• $86,158 — ended September 30, 2023 and 2022, and $86,158 and $1,603,169 for the nine months ende
• $1,603,169 — mber 30, 2023 and 2022, and $86,158 and $1,603,169 for the nine months ended September 30,
• $135,606 — (including amounts of related party of $135,606 and $115,912 for the three months ended
• $115,912 — mounts of related party of $135,606 and $115,912 for the three months ended September 30
• $287,802 — ended September 30, 2023 and 2022, and $287,802 and $490,082 for the nine months ended
• $490,082 — ber 30, 2023 and 2022, and $287,802 and $490,082 for the nine months ended September 30,

Filing Documents

• aimd_10qa.htm (10-Q/A) — 838KB
• aimd_ex101.htm (EX-10.1) — 30KB
• aimd_ex311.htm (EX-31.1) — 9KB
• aimd_ex312.htm (EX-31.2) — 12KB
• aimd_ex321.htm (EX-32.1) — 4KB
• aimd_ex322.htm (EX-32.2) — 4KB
• 0001654954-24-001834.txt (&nbsp;) — 3656KB
• aimd-20230930.xsd (EX-101.SCH) — 40KB
• aimd-20230930_lab.xml (EX-101.LAB) — 225KB
• aimd-20230930_cal.xml (EX-101.CAL) — 43KB
• aimd-20230930_pre.xml (EX-101.PRE) — 180KB
• aimd-20230930_def.xml (EX-101.DEF) — 90KB
• aimd_10qa_htm.xml (XML) — 450KB

Financial Statements

Financial Statements 3 Condensed Balance Sheets– September 30, 2023 and December 31, 2022 (unaudited) 3 Condensed Statements of Operations – Three and Nine Months Ended September 30, 2023 and 2022 (unaudited) 4 Condensed Statements of Comprehensive Loss – Three and Nine Months Ended September 30, 2023 and 2022 (unaudited) 5 Condensed Statements of Stockholders' Equity– Three Months Ended September 30, 2023 and 2022 (unaudited) 6 Condensed Statements of Stockholders' Equity– Nine Months Ended September 30, 2023 and 2022 (unaudited) 7 Condensed Statements of Cash Flows – Nine Months Ended September 30, 2023 and 2022 (unaudited) 8 Notes to Condensed Financial Statements (unaudited) 9 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 ITEM 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 ITEM 4.

Controls and Procedures

Controls and Procedures 24 PART II: OTHER INFORMATION ITEM 1.

Legal Proceedings

Legal Proceedings 25 ITEM 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 25 ITEM 3. Defaults Upon Senior Securities 25 ITEM 4. Mine Safety Disclosures 25 ITEM 5. Other Information 25 ITEM 6. Exhibits 26

Signatures

Signatures 27 2 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

ITEM 1. Financial Statements Ainos, Inc. Condensed Balance Sheets (Unaudited) September 30, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 2,370,963 $ 1,853,362 Accounts receivable (including amounts of related party of nil and $ 177,595 as of September 30, 2023 and December 31,2022, respectively) 162 201,546 Inventory, net 217,328 595,222 Other current assets 451,698 195,787 Total current assets 3,040,151 2,845,917 Intangible assets, net 29,422,937 32,806,738 Property and equipment, net 1,161,482 1,375,676 Other assets 235,215 80,683 Total assets $ 33,859,785 $ 37,109,014 Liabilities and Stockholders' Equity Current liabilities: Contract liabilities $ 111,717 $ - Convertible notes payable, related party - 376,526 Other notes payable, related party 42,000 884,000 Accrued expenses and others current liabilities 665,768 1,212,386 Total current liabilities 819,485 2,472,912 Convertible notes payable - noncurrent (including amounts of related party of $ 2,000,000 and nil as of September 30, 2023 and December 31, 2022, respectively) 3,000,000 - Senior secured convertible notes measured at fair value 2,000,000 - Other notes payable, related party - noncurrent 270,000 - Other long-term liabilities 89,333 8,096 Total liabilities 6,178,818 2,481,008 Commitments and contingencies Stockholders' equity: Preferred stock, $ 0.01 par value; 10,000,000 shares authorized; none issued Common stock, $ 0.01 par value; 300,000,000 shares authorized as of September 30, 2023 and December 31, 2022, 20,292,624 and 20,011,602 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively 202,926 200,116 Additional paid-in capital 59,763,987 58,745,149 Accumulated deficit ( 31,961,654 ) ( 24,115,606 ) Translation adjustment ( 324,292 ) ( 201,653 ) Total stockholders' equity 27,680,967 34,628,006 Tota

View Full Filing

View this 10-Q/A filing on SEC EDGAR